Helix BioPharma (TSE:HBP) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Shares of Helix BioPharma Corp. (TSE:HBP) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$1.59 and traded as high as C$1.93. Helix BioPharma shares last traded at C$1.93, with a volume of 1,711 shares.

Helix BioPharma Stock Performance

The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. The company’s 50-day moving average is C$1.60 and its two-hundred day moving average is C$1.71. The stock has a market capitalization of C$156.57 million, a P/E ratio of -51.25 and a beta of 0.43.

Helix BioPharma (TSE:HBP) last posted its earnings results on Friday, June 12th. The biopharmaceutical company reported C($0.01) EPS for the quarter. As a group, sell-side analysts anticipate that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.